Decision Memo for Cardiac Pacemakers (CAG-00063R2)

Decision Summary

CMS will revise CIM65-6 to focus the instruction on the indications for pacemaker use rather than on the pacemaker implantation procedure. This reflects our finding that pacemaker implantation is no longer an experimental procedure. The revised provisions will focus on the medical conditions that indicate that cardiac pacing is a reasonable and necessary treatment. In this decision memorandum, we change only this framework of the coverage determination and do not review the specific provisions setting forth conditions that indicate that cardiac pacing is reasonable and necessary.

Back to Top

Decision Memo

This decision memorandum does not constitute a national coverage determination (NCD). It states the intent of the Centers for Medicare & Medicaid Services (CMS) to issue an NCD. Though the policy is effective with publication of this decision, CMS must issue a manual instruction, program memorandum, CMS ruling or Federal Register Notice, giving specific directions to our claims processing contractors. That issuance is the NCD. If appropriate, the Agency must also change billing and claims processing systems and issue related instructions to allow for payment. The NCD will be published in the Medicare Coverage Issues Manual.

To: Administrative File: CAG 00063R2

Cardiac Pacemakers

From:

Steve E. Phurrough, MD, MPA Director, Coverage and Analysis Group

Marcel Salive, MD, MPH Division Director

Anthony Norris, MPA Lead Analyst

Lori Paserchia, MD Lead Medical Officer

Subject: Coverage Decision Memorandum for Cardiac Pacemakers

Date: March 12, 2004

I. Decision

CMS will revise CIM65-6 to focus the instruction on the indications for pacemaker use rather than on the pacemaker implantation procedure. This reflects our finding that pacemaker implantation is no longer an experimental procedure. The revised provisions will focus on the medical conditions that indicate that cardiac pacing is a reasonable and necessary treatment. In this decision memorandum, we change only this framework of the coverage determination and do not review the specific provisions setting forth conditions that indicate that cardiac pacing is reasonable and necessary.

II. Background

Cardiac Pacemakers

Cardiac pacemakers are generally implanted to alleviate symptoms of decreased cardiac output related to abnormal heart rate and/or rhythm. Without treatment, an abnormal heart rate can lead to weakness, confusion, dizziness, fainting, shortness of breath, and death. Pacemakers are generally used for persistent, symptomatic second- or third-degree AV block and symptomatic sinus bradycardia. For some patients, it may be appropriate to implant a pacemaker in order to continue pharmacological treatment. It is essential to document an association between symptoms and the dysrhythmia before pacemaker implantation.

The implantation procedure is typically performed under local anesthesia and requires only a brief hospitalization. A catheter is inserted into the chest and the pacemaker's leads are threaded through the catheter to the appropriate chamber(s) of the heart. The surgeon then makes a small "pocket" in the pad of flesh under the skin on the upper portion of the chest wall to hold the power source. The pocket is then closed with stitches. The procedure leaves a small scar and the battery can be felt through the skin.

Cardiac pacemakers are commonly accepted by the medical community as reasonable and necessary to treat many serious medical conditions.² There are some uses, however, that require considerable expertise and judgment and may not be supported by substantial scientific evidence, and therefore are not as commonly accepted. This distinction is already set forth in CIM-65-6 and we do not review the particular uses in this decision memorandum.

III. History of Medicare Coverage

Initial Coverage Request

Medicare's national coverage decision (NCD) for cardiac pacemakers can be found at CIM 65 -6. It was last updated in 1985, and limits the number of conditions for which CMS will pay for implantation of a cardiac pacemaker.

In June 2000, Medtronic requested that CMS review the use of a cardiac pacemaker to treat
asymptomatic bradycardia in post-MI patients about to initiate long-term ß-blocker drug
therapy. After a complete systematic review of the evidence provided, CMS posted a
coverage decision memorandum (CAG-00063N) on March 20, 2001, that maintained its
current non-coverage NCD that pacemaker implantation would not be considered reasonable
and necessary in these patients.

Reconsiderations

Medtronic Inc. (Medtronic) and Dr. Jeffery J. Goldberger of Northwestern University each requested reconsideration of CAG-00063N. We accepted these requests as a single reconsideration. A number of concerns about the CMS analysis in this NCA were raised in the letters submitted by Medtronic and Dr. Goldberger, dated April 3 and April 4, 2001 respectively, (which we accepted as a single reconsideration). These concerns are delineated in CAG00063R. Medicare maintained its policy to not cover pacemaker implantation for post-MI patients with asymptomatic bradycardia.

On October 24, 2003, CMS began a national coverage determination reconsideration process for cardiac pacemaker. The present language speaks to "the medical necessity, or lack thereof, for pacemaker implantation..." The current reconsideration is to determine whether CMS should revise the current NCD to remove pacemaker implantation as the technology for which a reasonable and necessary determination should be made. In order to appropriately assess the benefits of various pacemakers for a number of old and new indications, it is necessary to separate "implantation" from clinical use of a pacemaker in making reasonable and necessary determinations.

IV. Timeline of Recent Activities

October 24, 2003	CMS opens an NCD and requests public comment on the appropriateness of removing implantation of pacemakers as the technology for which a reasonable and necessary determination should be made.

V. FDA Status


The FDA status for pacemakers can be reviewed in CAG 00063N.


VI. Evidence

The purpose of this NCD is to determine the appropriateness of removing implantation of pacemakers as the issue for which a reasonable and necessary determination is made for use of cardiac pacing.

Pacemaker implantation is described above. Less than 2% of patients suffer from complications due to pacemaker implantation. Examples of complications that may occur as a result of pacemaker implantation are not radically different from those that occur with other catheterization procedures, e.g., bleeding, punctured vein, infection, or collapsed lung.³

Professional Society Position Statements





1 Bennett, J. Claude, Goldman, Lee. Cecil Textbook of Medicine. 2000; 1: 249.

2 Silverman BG, Gross TP, Kaczmareki, Hamilton P and Hamburger. The epidemiology of pacemaker implantation in the United States. *Public Health Reports* 1995;110(1):42-46 and Daley WR, Kaczmarek RG. The epidemiology of cardiac pacemakers in the older US population. *Journal of the American Geriatrics Society* 1998;46(8):1016-1019.

3 See Cardiac Pacemaker Decision Memorandum (CAG 00063N) and Pavia S, Wildoff B. The management of surgical complications of pacemaker and implantable cardioverter-defibrillators. *Current Opinion in Cardiology* 2001;16(1):66-71.

4 Yamamura KH, Kloosterman EM, Alba J et al. Analysis of charges and complications of permanent pacemaker implantation in the cardiac catheterization laboratory versus the operating room. *Pacing and Clinical Electrophysiology* 1999;22(12):1820-1824.

Back to Top